M. Schlichting

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann et al. · Annals of Oncology · 2011 · 782 citations · Full text

Medicine, Oncology, Pharmacology +14

Combined Calcium and Vitamin D3 Supplementation in Elderly Women: Confirmation of Reversal of Secondary Hyperparathyroidism and Hip Fracture Risk: The Decalyos II Study

M. C. Chapuy, Raymond Pamphile, E. Paris et al. · Osteoporosis International · 2002 · 550 citations

Medicine, Endocrinology, Nutritional Sciences +14

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)

Hubert Piessevaux, Marc Buyse, Wendy De Roock et al. · Annals of Oncology · 2009 · 83 citations

Medicine, Oncology, Radiology +11

Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to <i>KRAS</i> and <i>BRAF</i> mutation status.

Carsten Bokemeyer, Claus Henning Köhne, P. Rougier et al. · Journal of Clinical Oncology · 2010 · 82 citations

Medicine, Oncology, Pharmacotherapy +16

Influence of <i>KRAS </i>G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab.

Sabine Tejpar, Carsten Bokemeyer, İ. Çelik et al. · Journal of Clinical Oncology · 2011 · 43 citations

Medicine, Oncology, Pharmacology +13